Dr. Reddys Laboratories Ltd.

With reference to Regulation 30(11) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’) regarding a news item published in The Economic Times (newspaper/ media) on April 15, 2025, with the heading ‘Sweet Surrender: Sanofi puts star insulin brand on block’. The said news item states that Sanofi India has started the process of selling its flagship insulin brand, Lantus, with major domestic pharmaceutical companies and has mentioned Dr. Reddy's Laboratories as one of the potential acquirers. In this regard, Dr. Reddy’s Laboratories has informed that the Company does not comment on market speculations and there is currently no such event or information which requires a disclosure under Regulation 30 of the SEBI Listing Regulations. In compliance with Regulation 30 of the SEBI Listing Regulations, the Company makes prompt disclosure of any event or information, as and when any event or information is considered material or warrants such disclosure under the said Regulation.

The above information is a part of company’s filings submitted to BSE.